
Epizyme EPZM
Quarterly report 2022-Q2
added 08-09-2022
Epizyme Depreciation & Amortization 2011-2026 | EPZM
Annual Depreciation & Amortization Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.25 M | 3.98 M | 840 K | 1.05 M | 1.64 M | 1.59 M | 1.42 M | 742 K | 703 K | 847 K | 479 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.25 M | 479 K | 1.69 M |
Quarterly Depreciation & Amortization Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.58 M | 1.3 M | - | 1 M | 2.6 M | 1.28 M | - | 2.67 M | 1.36 M | 512 K | - | 626 K | 416 K | 207 K | - | 804 K | 582 K | 361 K | - | 1.23 M | 824 K | 411 K | - | 1.19 M | 791 K | 389 K | - | 1.06 M | 653 K | 260 K | - | 548 K | 362 K | 169 K | - | 534 K | 363 K | 179 K | - | 440 K | 292 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.67 M | 169 K | 838 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 21.77 | 1.68 % | $ 1.02 B | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 0.92 | 3.05 % | $ 6.76 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.44 | 2.16 % | $ 3.72 B | ||
|
Esperion Therapeutics
ESPR
|
105 K | $ 2.02 | 5.76 % | $ 420 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Galectin Therapeutics
GALT
|
1 K | $ 2.42 | 3.65 % | $ 155 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Heron Therapeutics
HRTX
|
2.31 M | $ 1.26 | 6.3 % | $ 210 M | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
ImmuCell Corporation
ICCC
|
2.78 M | $ 8.28 | -0.84 % | $ 74.7 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
487 K | - | 17.91 % | $ 11.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
548 K | $ 4.14 | 1.47 % | $ 443 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 23.57 | 1.33 % | $ 3 B | ||
|
Jaguar Health
JAGX
|
1.91 M | $ 0.36 | -8.39 % | $ 840 K | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.46 | 1.04 % | $ 389 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
KalVista Pharmaceuticals
KALV
|
969 K | $ 20.08 | 2.29 % | $ 1.08 B | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 2.99 | 2.05 % | $ 4.92 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B |